Sugi Predict

Sugi Predict / Compounds / SCHEMBL1494587

SCHEMBL1494587

SCHEMBL1494587

Fc1cc(Br)c(F)c(Br)c1

nearest known ligand 0.38

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 1/20 0.38
▸ CA12 O43570 1/20 0.35
▸ CA1 P00915 1/20 0.35
▸ CA9 Q16790 1/20 0.35
▸ MAPT P10636 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ EGFR P00533 1/20 0.31
▸ CES2 O00748 2/20 0.31
▸ CES1 P23141 2/20 0.31
▸ PKM P14618 1/20 0.30
▸ APEX1 P27695 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL504762 0.84 CES2 (0.42) GAACA12CA1CA9MAPT
SCHEMBL29382820 0.84 CES2 (0.42) GAACA12CA1CA9MAPT
SCHEMBL30543313 0.80 GAA (0.32) GAA
SCHEMBL22112025 0.80 CA9 (0.39) GAACA12CA1CA9MAPT
SCHEMBL30193061 0.80 CA9 (0.39) GAACA12CA1CA9MAPT
SCHEMBL18302718 0.80 GAA (0.32) GAA
SCHEMBL13550024 0.80 ALDH1A1 (0.33) GAA
SCHEMBL1494366 0.80 GAA (0.36) GAACA1CA9MAPTKMT2A
SCHEMBL29851037 0.80 GAA (0.36) GAACA1CA9MAPTKMT2A
SCHEMBL7935640 0.79 TDP1 (0.47) CA1CA9MAPTKMT2AAPEX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260103471-A1 CYCLIC UREA THIAZOLYL COMPOUNDS FOR TREATMENT OF HSV ASSEMBLY BIOSCIENCES INC (US) 2026-04-16 — — US disclosed
US-12528818-B2 Compositions and methods for inhibition of RAS LEIDOS BIOMEDICAL RESEARCH, INC. (US) 2026-01-20 — — US disclosed
US-12503475-B2 Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists CENTESSA PHARMACEUTICALS (UK) LIMITED (GB) 2025-12-23 — — US disclosed
US-20250376478-A1 CYCLIC UREA THIAZOLYL COMPOUNDS FOR TREATMENT OF HSV ASSEMBLY BIOSCIENCES INC (US) 2025-12-11 — — US disclosed
US-20250270225-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF RAS NNSA 2025-08-28 — — US disclosed
EP-4581029-A1 CYCLIC UREA THIAZOLYL COMPOUNDS FOR TREATMENT OF HSV Assembly Biosciences, Inc. (US) 2025-07-09 — — EP disclosed
CN-117050073-B Polysubstituted phenyl bisimidazopyridine compound and synthetic method and application thereof 中国药科大学 2025-06-10 — — CN disclosed
WO-2025072395-A1 TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2025-04-03 — — WO disclosed
US-20250100968-A1 BICYCLIC-HETEROCYCLE DERIVATIVES AND RELATED USES OXFORD FINANCE LLC 2025-03-27 — — US disclosed
WO-2025016432-A1 COMPOUND HAVING ANTI-KRAS MUTANT TUMOR ACTIVITY 泰励生物科技（上海）有限公司 2025-01-23 — — WO disclosed
US-8563553-B2 Compounds and compositions as protein kinase inhibitors NOVARTIS AG (CH) 2013-10-22 — — US disclosed
US-20120225899-A1 Compounds and Compositions as Protein Kinase Inhibitors NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-09-06 — — US disclosed
US-8242260-B2 Compounds and compositions as protein kinase inhibitors NOVARTIS AG (CH) 2012-08-14 — — US disclosed
EP-2470528-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS Novartis AG (CH) 2012-07-04 — — EP disclosed
WO-2011023773-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS NOVARTIS AG (CH) 2011-03-03 — — WO disclosed
US-20110052578-A1 Compounds and Compositions as Protein Kinase Inhibitors NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2011-03-03 — — US disclosed
EP-2173745-A2 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS Array Biopharma, Inc. (US) 2010-04-14 — — EP disclosed
WO-2008118718-A2 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2008-10-02 — — WO disclosed
EP-0934237-A1 TETRACYCLIC COMPOUND HAVING LATERAL HALOGEN SUBSTITUENT AND LIQUID CRYSTAL COMPOSITION COMPRISING THE SAME CHISSO CORPORATION (JP) 1999-08-11 — — EP disclosed
WO-1998008792-A1 TETRACYCLIC COMPOUND HAVING LATERAL HALOGEN SUBSTITUENT AND LIQUID CRYSTAL COMPOSITION COMPRISING THE SAME CHISSO CORPORATION (JP) 1998-03-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12503475-B2 Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists HCRTR2, HCRTR1, CRHR2 GAA 1870/4885CA12 3110/4885CA1 1459/4885
US-20110052578-A1 Compounds and Compositions as Protein Kinase Inhibitors RAF1, BRAF, ARAF GAA 3924/4885CA12 4776/4885CA1 4630/4885
US-20260103471-A1 CYCLIC UREA THIAZOLYL COMPOUNDS FOR TREATMENT OF HSV TK1, UNG, SMCHD1 GAA 2649/4885CA12 1447/4885CA1 3419/4885
US-20250270225-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF RAS KRAS, NRAS, HRAS GAA 889/4885CA12 1241/4885CA1 815/4885
US-20120225899-A1 Compounds and Compositions as Protein Kinase Inhibitors RAF1, BRAF, ARAF GAA 3924/4885CA12 4776/4885CA1 4630/4885
US-20250100968-A1 BICYCLIC-HETEROCYCLE DERIVATIVES AND RELATED USES HCRTR2, HCRTR1, CRHR1 GAA 1022/4885CA12 3745/4885CA1 1504/4885
US-12528818-B2 Compositions and methods for inhibition of RAS KRAS, NRAS, HRAS GAA 3748/4885CA12 433/4885CA1 1013/4885
US-20250376478-A1 CYCLIC UREA THIAZOLYL COMPOUNDS FOR TREATMENT OF HSV TYMP, TK1, TREH GAA 390/4885CA12 1401/4885CA1 1636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.